A Companion Cancer Diagnostics is a diagnostic test used as a companion to a therapeutic drug to determine its applicability to a specific person.
Companion Cancer Diagnostics are co-developed with drugs to aid in selecting or excluding patient groups for treatment with that particular drug on the basis of their biological characteristics that determine responders and non-responders to the therapy.
The research report studies the Companion Cancer Diagnostics market using different methodologies and analyzes to provide accurate and in-depth information about the market. For a clearer understanding, it is divided into several parts to cover different aspects of the market. Each area is then elaborated to help the reader comprehend the growth potential of each region and its contribution to the global market. The researchers have used primary and secondary methodologies to collate the information in the report. They have also used the same data to generate the current market scenario. This report is aimed at guiding people towards an apprehensive, better, and clearer knowledge of the market.
Global Companion Cancer Diagnostics market: Drivers and Restraints
This section covers the various factors driving the global Companion Cancer Diagnostics market. To understand the growth of the market it is important to analyze the various drivers present the market. It provides data by value and volume of different regions and their respective manufacturers. This data will elaborate on the market share occupied by them, predict their revenue concerning strategies, and how they will grow in the future. After explaining the drivers, the report further evaluates the new opportunities and current trends in the market.
Market restraints are factors hampering market growth. Studying these factors is equally pivotal as they help a reader need understand the weaknesses of the market.
Global Companion Cancer Diagnostics market: Segment Analysis
The global Companion Cancer Diagnostics market is split into two segments, type, and application. The product type briefs on the various types of products available in the market. The report also provides data for each product type by revenue for the forecast time period. It covers the price of each type of product. The other segment on the report, application, explains the various uses of the product and end-users. In the report, the researchers have also provided revenue according to the consumption of the product.
Global Companion Cancer Diagnostics market: Regional Analysis
The major regions covered in the report are North America, Europe, China, Rest of Asia Pacific, Central & South America, Middle East & Africa, etc. It includes revenue analysis of each region for the year 2015 to 2026.
Global Companion Cancer Diagnostics market: Key Players
The report lists the major players in the regions and their respective market share on the basis of global revenue. It also explains their strategic moves in the past few years, investments in product innovation, and changes in leadership to stay ahead in the competition. This will give the reader an edge over others as a well-informed decision can be made looking at the holistic picture of the market.
By the type, the market is primarily split into
Breast Cancer
Lung Cancer
Colorectal Cancer
Melanoma
Gastric Cancer
By the application, this report covers the following segments
Pharmaceutical & Biopharmaceutical Companies
Reference Laboratories
CROs
Others
Competitive Landscape:
The Companion Cancer Diagnostics key manufacturers in this market include:
F. Hoffmann-La Roche
Agilent Technologies
QIAGEN
Abbott Laboratories
Almac Group
Danaher Corporation
bioMérieuxSA
Myriad Genetics
Companion Cancer Diagnostics are co-developed with drugs to aid in selecting or excluding patient groups for treatment with that particular drug on the basis of their biological characteristics that determine responders and non-responders to the therapy.
The research report studies the Companion Cancer Diagnostics market using different methodologies and analyzes to provide accurate and in-depth information about the market. For a clearer understanding, it is divided into several parts to cover different aspects of the market. Each area is then elaborated to help the reader comprehend the growth potential of each region and its contribution to the global market. The researchers have used primary and secondary methodologies to collate the information in the report. They have also used the same data to generate the current market scenario. This report is aimed at guiding people towards an apprehensive, better, and clearer knowledge of the market.
Global Companion Cancer Diagnostics market: Drivers and Restraints
This section covers the various factors driving the global Companion Cancer Diagnostics market. To understand the growth of the market it is important to analyze the various drivers present the market. It provides data by value and volume of different regions and their respective manufacturers. This data will elaborate on the market share occupied by them, predict their revenue concerning strategies, and how they will grow in the future. After explaining the drivers, the report further evaluates the new opportunities and current trends in the market.
Market restraints are factors hampering market growth. Studying these factors is equally pivotal as they help a reader need understand the weaknesses of the market.
Global Companion Cancer Diagnostics market: Segment Analysis
The global Companion Cancer Diagnostics market is split into two segments, type, and application. The product type briefs on the various types of products available in the market. The report also provides data for each product type by revenue for the forecast time period. It covers the price of each type of product. The other segment on the report, application, explains the various uses of the product and end-users. In the report, the researchers have also provided revenue according to the consumption of the product.
Global Companion Cancer Diagnostics market: Regional Analysis
The major regions covered in the report are North America, Europe, China, Rest of Asia Pacific, Central & South America, Middle East & Africa, etc. It includes revenue analysis of each region for the year 2015 to 2026.
Global Companion Cancer Diagnostics market: Key Players
The report lists the major players in the regions and their respective market share on the basis of global revenue. It also explains their strategic moves in the past few years, investments in product innovation, and changes in leadership to stay ahead in the competition. This will give the reader an edge over others as a well-informed decision can be made looking at the holistic picture of the market.
By the type, the market is primarily split into
Breast Cancer
Lung Cancer
Colorectal Cancer
Melanoma
Gastric Cancer
By the application, this report covers the following segments
Pharmaceutical & Biopharmaceutical Companies
Reference Laboratories
CROs
Others
Competitive Landscape:
The Companion Cancer Diagnostics key manufacturers in this market include:
F. Hoffmann-La Roche
Agilent Technologies
QIAGEN
Abbott Laboratories
Almac Group
Danaher Corporation
bioMérieuxSA
Myriad Genetics
Table of Contents
1 Market Overview of Companion Cancer Diagnostics
1.1 Companion Cancer Diagnostics Market Overview
1.1.1 Companion Cancer Diagnostics Product Scope
1.1.2 Market Status and Outlook
1.2 Global Companion Cancer Diagnostics Market Size Overview by Region 2015 VS 2020 VS 2026
1.3 Global Companion Cancer Diagnostics Market Size by Region (2015-2026)
1.4 Global Companion Cancer Diagnostics Historic Market Size by Region (2015-2020)
1.5 Global Companion Cancer Diagnostics Market Size Forecast by Region (2021-2026)
1.6 Key Regions Companion Cancer Diagnostics Market Size YoY Growth (2015-2026)
1.6.1 North America Companion Cancer Diagnostics Market Size YoY Growth (2015-2026)
1.6.2 Europe Companion Cancer Diagnostics Market Size YoY Growth (2015-2026)
1.6.3 China Companion Cancer Diagnostics Market Size YoY Growth (2015-2026)
1.6.4 Rest of Asia Pacific Companion Cancer Diagnostics Market Size YoY Growth (2015-2026)
1.6.5 Latin America Companion Cancer Diagnostics Market Size YoY Growth (2015-2026)
1.6.6 Middle East & Africa Companion Cancer Diagnostics Market Size YoY Growth (2015-2026)
2 Companion Cancer Diagnostics Market Overview by Type
2.1 Global Companion Cancer Diagnostics Market Size by Type: 2015 VS 2020 VS 2026
2.2 Global Companion Cancer Diagnostics Historic Market Size by Type (2015-2020)
2.3 Global Companion Cancer Diagnostics Forecasted Market Size by Type (2021-2026)
2.4 Breast Cancer
2.5 Lung Cancer
2.6 Colorectal Cancer
2.7 Melanoma
2.8 Gastric Cancer
3 Companion Cancer Diagnostics Market Overview by Type
3.1 Global Companion Cancer Diagnostics Market Size by Application: 2015 VS 2020 VS 2026
3.2 Global Companion Cancer Diagnostics Historic Market Size by Application (2015-2020)
3.3 Global Companion Cancer Diagnostics Forecasted Market Size by Application (2021-2026)
3.4 Pharmaceutical & Biopharmaceutical Companies
3.5 Reference Laboratories
3.6 CROs
3.7 Others
4 Global Companion Cancer Diagnostics Competition Analysis by Players
4.1 Global Companion Cancer Diagnostics Market Size (Million US$) by Players (2015-2020)
4.2 Global Top Manufacturers by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Companion Cancer Diagnostics as of 2019)
4.3 Date of Key Manufacturers Enter into Companion Cancer Diagnostics Market
4.4 Global Top Players Companion Cancer Diagnostics Headquarters and Area Served
4.5 Key Players Companion Cancer Diagnostics Product Solution and Service
4.6 Competitive Status
4.6.1 Companion Cancer Diagnostics Market Concentration Rate
4.6.2 Mergers & Acquisitions, Expansion Plans
5 Company (Top Players) Profiles and Key Data
5.1 F. Hoffmann-La Roche
5.1.1 F. Hoffmann-La Roche Profile
5.1.2 F. Hoffmann-La Roche Main Business and Company’s Total Revenue
5.1.3 F. Hoffmann-La Roche Products, Services and Solutions
5.1.4 F. Hoffmann-La Roche Revenue (US$ Million) (2015-2020)
5.1.5 F. Hoffmann-La Roche Recent Developments
5.2 Agilent Technologies
5.2.1 Agilent Technologies Profile
5.2.2 Agilent Technologies Main Business and Company’s Total Revenue
5.2.3 Agilent Technologies Products, Services and Solutions
5.2.4 Agilent Technologies Revenue (US$ Million) (2015-2020)
5.2.5 Agilent Technologies Recent Developments
5.3 QIAGEN
5.5.1 QIAGEN Profile
5.3.2 QIAGEN Main Business and Company’s Total Revenue
5.3.3 QIAGEN Products, Services and Solutions
5.3.4 QIAGEN Revenue (US$ Million) (2015-2020)
5.3.5 Abbott Laboratories Recent Developments
5.4 Abbott Laboratories
5.4.1 Abbott Laboratories Profile
5.4.2 Abbott Laboratories Main Business and Company’s Total Revenue
5.4.3 Abbott Laboratories Products, Services and Solutions
5.4.4 Abbott Laboratories Revenue (US$ Million) (2015-2020)
5.4.5 Abbott Laboratories Recent Developments
5.5 Almac Group
5.5.1 Almac Group Profile
5.5.2 Almac Group Main Business and Company’s Total Revenue
5.5.3 Almac Group Products, Services and Solutions
5.5.4 Almac Group Revenue (US$ Million) (2015-2020)
5.5.5 Almac Group Recent Developments
5.6 Danaher Corporation
5.6.1 Danaher Corporation Profile
5.6.2 Danaher Corporation Main Business and Company’s Total Revenue
5.6.3 Danaher Corporation Products, Services and Solutions
5.6.4 Danaher Corporation Revenue (US$ Million) (2015-2020)
5.6.5 Danaher Corporation Recent Developments
5.7 bioMérieuxSA
5.7.1 bioMérieuxSA Profile
5.7.2 bioMérieuxSA Main Business and Company’s Total Revenue
5.7.3 bioMérieuxSA Products, Services and Solutions
5.7.4 bioMérieuxSA Revenue (US$ Million) (2015-2020)
5.7.5 bioMérieuxSA Recent Developments
5.8 Myriad Genetics
5.8.1 Myriad Genetics Profile
5.8.2 Myriad Genetics Main Business and Company’s Total Revenue
5.8.3 Myriad Genetics Products, Services and Solutions
5.8.4 Myriad Genetics Revenue (US$ Million) (2015-2020)
5.8.5 Myriad Genetics Recent Developments
6 North America Companion Cancer Diagnostics by Players and by Application
6.1 North America Companion Cancer Diagnostics Market Size and Market Share by Players (2015-2020)
6.2 North America Companion Cancer Diagnostics Market Size by Application (2015-2020)
7 Europe Companion Cancer Diagnostics by Players and by Application
7.1 Europe Companion Cancer Diagnostics Market Size and Market Share by Players (2015-2020)
7.2 Europe Companion Cancer Diagnostics Market Size by Application (2015-2020)
8 China Companion Cancer Diagnostics by Players and by Application
8.1 China Companion Cancer Diagnostics Market Size and Market Share by Players (2015-2020)
8.2 China Companion Cancer Diagnostics Market Size by Application (2015-2020)
9 Rest of Asia Pacific Companion Cancer Diagnostics by Players and by Application
9.1 Rest of Asia Pacific Companion Cancer Diagnostics Market Size and Market Share by Players (2015-2020)
9.2 Rest of Asia Pacific Companion Cancer Diagnostics Market Size by Application (2015-2020)
10 Latin America Companion Cancer Diagnostics by Players and by Application
10.1 Latin America Companion Cancer Diagnostics Market Size and Market Share by Players (2015-2020)
10.2 Latin America Companion Cancer Diagnostics Market Size by Application (2015-2020)
11 Middle East & Africa Companion Cancer Diagnostics by Players and by Application
11.1 Middle East & Africa Companion Cancer Diagnostics Market Size and Market Share by Players (2015-2020)
11.2 Middle East & Africa Companion Cancer Diagnostics Market Size by Application (2015-2020)
12 Companion Cancer Diagnostics Market Dynamics
12.1 Industry Trends
12.2 Market Drivers
12.3 Market Challenges
12.4 Porter’s Five Forces Analysis
13 Research Finding /Conclusion
14 Methodology and Data Source
14.1 Methodology/Research Approach
14.1.1 Research Programs/Design
14.1.2 Market Size Estimation
14.1.3 Market Breakdown and Data Triangulation
14.2 Data Source
14.2.1 Secondary Sources
14.2.2 Primary Sources
14.3 Disclaimer
14.4 Author List
1 Market Overview of Companion Cancer Diagnostics
1.1 Companion Cancer Diagnostics Market Overview
1.1.1 Companion Cancer Diagnostics Product Scope
1.1.2 Market Status and Outlook
1.2 Global Companion Cancer Diagnostics Market Size Overview by Region 2015 VS 2020 VS 2026
1.3 Global Companion Cancer Diagnostics Market Size by Region (2015-2026)
1.4 Global Companion Cancer Diagnostics Historic Market Size by Region (2015-2020)
1.5 Global Companion Cancer Diagnostics Market Size Forecast by Region (2021-2026)
1.6 Key Regions Companion Cancer Diagnostics Market Size YoY Growth (2015-2026)
1.6.1 North America Companion Cancer Diagnostics Market Size YoY Growth (2015-2026)
1.6.2 Europe Companion Cancer Diagnostics Market Size YoY Growth (2015-2026)
1.6.3 China Companion Cancer Diagnostics Market Size YoY Growth (2015-2026)
1.6.4 Rest of Asia Pacific Companion Cancer Diagnostics Market Size YoY Growth (2015-2026)
1.6.5 Latin America Companion Cancer Diagnostics Market Size YoY Growth (2015-2026)
1.6.6 Middle East & Africa Companion Cancer Diagnostics Market Size YoY Growth (2015-2026)
2 Companion Cancer Diagnostics Market Overview by Type
2.1 Global Companion Cancer Diagnostics Market Size by Type: 2015 VS 2020 VS 2026
2.2 Global Companion Cancer Diagnostics Historic Market Size by Type (2015-2020)
2.3 Global Companion Cancer Diagnostics Forecasted Market Size by Type (2021-2026)
2.4 Breast Cancer
2.5 Lung Cancer
2.6 Colorectal Cancer
2.7 Melanoma
2.8 Gastric Cancer
3 Companion Cancer Diagnostics Market Overview by Type
3.1 Global Companion Cancer Diagnostics Market Size by Application: 2015 VS 2020 VS 2026
3.2 Global Companion Cancer Diagnostics Historic Market Size by Application (2015-2020)
3.3 Global Companion Cancer Diagnostics Forecasted Market Size by Application (2021-2026)
3.4 Pharmaceutical & Biopharmaceutical Companies
3.5 Reference Laboratories
3.6 CROs
3.7 Others
4 Global Companion Cancer Diagnostics Competition Analysis by Players
4.1 Global Companion Cancer Diagnostics Market Size (Million US$) by Players (2015-2020)
4.2 Global Top Manufacturers by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Companion Cancer Diagnostics as of 2019)
4.3 Date of Key Manufacturers Enter into Companion Cancer Diagnostics Market
4.4 Global Top Players Companion Cancer Diagnostics Headquarters and Area Served
4.5 Key Players Companion Cancer Diagnostics Product Solution and Service
4.6 Competitive Status
4.6.1 Companion Cancer Diagnostics Market Concentration Rate
4.6.2 Mergers & Acquisitions, Expansion Plans
5 Company (Top Players) Profiles and Key Data
5.1 F. Hoffmann-La Roche
5.1.1 F. Hoffmann-La Roche Profile
5.1.2 F. Hoffmann-La Roche Main Business and Company’s Total Revenue
5.1.3 F. Hoffmann-La Roche Products, Services and Solutions
5.1.4 F. Hoffmann-La Roche Revenue (US$ Million) (2015-2020)
5.1.5 F. Hoffmann-La Roche Recent Developments
5.2 Agilent Technologies
5.2.1 Agilent Technologies Profile
5.2.2 Agilent Technologies Main Business and Company’s Total Revenue
5.2.3 Agilent Technologies Products, Services and Solutions
5.2.4 Agilent Technologies Revenue (US$ Million) (2015-2020)
5.2.5 Agilent Technologies Recent Developments
5.3 QIAGEN
5.5.1 QIAGEN Profile
5.3.2 QIAGEN Main Business and Company’s Total Revenue
5.3.3 QIAGEN Products, Services and Solutions
5.3.4 QIAGEN Revenue (US$ Million) (2015-2020)
5.3.5 Abbott Laboratories Recent Developments
5.4 Abbott Laboratories
5.4.1 Abbott Laboratories Profile
5.4.2 Abbott Laboratories Main Business and Company’s Total Revenue
5.4.3 Abbott Laboratories Products, Services and Solutions
5.4.4 Abbott Laboratories Revenue (US$ Million) (2015-2020)
5.4.5 Abbott Laboratories Recent Developments
5.5 Almac Group
5.5.1 Almac Group Profile
5.5.2 Almac Group Main Business and Company’s Total Revenue
5.5.3 Almac Group Products, Services and Solutions
5.5.4 Almac Group Revenue (US$ Million) (2015-2020)
5.5.5 Almac Group Recent Developments
5.6 Danaher Corporation
5.6.1 Danaher Corporation Profile
5.6.2 Danaher Corporation Main Business and Company’s Total Revenue
5.6.3 Danaher Corporation Products, Services and Solutions
5.6.4 Danaher Corporation Revenue (US$ Million) (2015-2020)
5.6.5 Danaher Corporation Recent Developments
5.7 bioMérieuxSA
5.7.1 bioMérieuxSA Profile
5.7.2 bioMérieuxSA Main Business and Company’s Total Revenue
5.7.3 bioMérieuxSA Products, Services and Solutions
5.7.4 bioMérieuxSA Revenue (US$ Million) (2015-2020)
5.7.5 bioMérieuxSA Recent Developments
5.8 Myriad Genetics
5.8.1 Myriad Genetics Profile
5.8.2 Myriad Genetics Main Business and Company’s Total Revenue
5.8.3 Myriad Genetics Products, Services and Solutions
5.8.4 Myriad Genetics Revenue (US$ Million) (2015-2020)
5.8.5 Myriad Genetics Recent Developments
6 North America Companion Cancer Diagnostics by Players and by Application
6.1 North America Companion Cancer Diagnostics Market Size and Market Share by Players (2015-2020)
6.2 North America Companion Cancer Diagnostics Market Size by Application (2015-2020)
7 Europe Companion Cancer Diagnostics by Players and by Application
7.1 Europe Companion Cancer Diagnostics Market Size and Market Share by Players (2015-2020)
7.2 Europe Companion Cancer Diagnostics Market Size by Application (2015-2020)
8 China Companion Cancer Diagnostics by Players and by Application
8.1 China Companion Cancer Diagnostics Market Size and Market Share by Players (2015-2020)
8.2 China Companion Cancer Diagnostics Market Size by Application (2015-2020)
9 Rest of Asia Pacific Companion Cancer Diagnostics by Players and by Application
9.1 Rest of Asia Pacific Companion Cancer Diagnostics Market Size and Market Share by Players (2015-2020)
9.2 Rest of Asia Pacific Companion Cancer Diagnostics Market Size by Application (2015-2020)
10 Latin America Companion Cancer Diagnostics by Players and by Application
10.1 Latin America Companion Cancer Diagnostics Market Size and Market Share by Players (2015-2020)
10.2 Latin America Companion Cancer Diagnostics Market Size by Application (2015-2020)
11 Middle East & Africa Companion Cancer Diagnostics by Players and by Application
11.1 Middle East & Africa Companion Cancer Diagnostics Market Size and Market Share by Players (2015-2020)
11.2 Middle East & Africa Companion Cancer Diagnostics Market Size by Application (2015-2020)
12 Companion Cancer Diagnostics Market Dynamics
12.1 Industry Trends
12.2 Market Drivers
12.3 Market Challenges
12.4 Porter’s Five Forces Analysis
13 Research Finding /Conclusion
14 Methodology and Data Source
14.1 Methodology/Research Approach
14.1.1 Research Programs/Design
14.1.2 Market Size Estimation
14.1.3 Market Breakdown and Data Triangulation
14.2 Data Source
14.2.1 Secondary Sources
14.2.2 Primary Sources
14.3 Disclaimer
14.4 Author List
